What was recalled
The U.S. Food and Drug Administration (FDA) has issued a recall involving a specific pharmaceutical ingredient manufactured by Shoolin Pharma Chem LLP. This is not a finished medication you would typically pick up at a pharmacy counter, but rather a raw active pharmaceutical ingredient intended for use in compounding pharmacies. The product in question is Sildenafil Citrate USP, provided in 100-gram bags with a net weight of 0.100 KG. The labeling clearly marks the material as "RX ONLY" and explicitly states that it is "FOR Prescription Compounding Only," indicating its restricted use to licensed professionals who prepare customized medications for individual patients.
The specific batch affected by this recall is identified by the batch number SDC2505001. This particular inventory carries a National Drug Code (NDC) of 85702-001-05 and is associated with the Chemical Abstracts Service registry number (CAS NO.) 171599-83-0, which helps uniquely identify the chemical structure of Sildenafil Citrate. The product bears an expiration date of April 30, 2030, meaning the issue is not related to spoilage over time, but rather to the conditions under which it was manufactured.
The recall was announced on August 3, 2026, and applies to units that were distributed nationwide across the United States. Shoolin Pharma Chem LLP, the entity responsible for this product, is located in Gujarat, India, specifically at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesana, 382715. Because the distribution pattern covers the entire country, compounding pharmacies and healthcare providers across all states may have received this material prior to the recall notice.
This action is classified as a Class II recall by the FDA. A Class II classification indicates that the use of or exposure to the violative product may cause temporary or medically reversible serious adverse health consequences, or where the probability of serious adverse health consequences is remote. While the official remedy for this specific recall has not been stated in the current records, the identification of the hazard as "CGMP Deviations: Noted during FDA inspection" suggests that the manufacturing process did not meet current Good Manufacturing Practice standards. This deviation is the primary reason for the withdrawal, ensuring that healthcare providers do not use potentially non-compliant ingredients in their compounded prescriptions.
The hazard, explained
When the FDA classifies a recall as Class II, it signals that the product in question may cause temporary health problems or pose only a slight threat of serious injury. However, "slight" is not a word we should use lightly when it comes to prescription medications, particularly those involved in complex chemical processes like compounding. In this specific case, the core issue identified by the FDA was a deviation from Current Good Manufacturing Practices, commonly known as CGMP. To understand why this matters, we first need to look at what CGMP actually is and why its absence creates a tangible risk for consumers.
CGMP regulations are not just bureaucratic hurdles; they are the essential safeguards that ensure every single pill or bag of powder meets strict standards for identity, strength, quality, and purity. When a manufacturer deviates from these practices, it means that specific checkpoints in the production line were either missed, poorly executed, or inadequately documented. For a substance like Sildenafil Citrate USP, which is an active pharmaceutical ingredient used primarily to treat erectile dysfunction and pulmonary arterial hypertension, consistency is everything. The drug must contain exactly what the label says it contains, in the exact amount specified, free from contaminants that could interfere with its function or safety.
The physical mechanism of harm here stems from unpredictability. If CGMP protocols are not followed, several things can go wrong within that 100-gram bag of powder distributed nationwide. First, there is the risk of incorrect potency. The Sildenafil Citrate might be under-dosed, rendering the compounded medication ineffective for patients who rely on it for critical blood pressure management or other cardiovascular needs. Alternatively, it could be over-dosed, leading to dangerous drops in blood pressure, severe headaches, vision changes, or priapism—a prolonged and painful erection that can cause permanent tissue damage if not treated immediately.
Second, there is the risk of contamination. Good manufacturing practices require rigorous environmental controls and equipment sterilization. A deviation here could mean the introduction of microbial contaminants, heavy metals, or cross-contamination from other chemicals in the facility. Even trace amounts of impurities can trigger allergic reactions, toxic responses, or interfere with how the liver processes the drug. Because this product is labeled "For Prescription Compounding Only," it is intended to be mixed by pharmacists into final doses for individual patients. If the base ingredient itself is inconsistent or contaminated, every single dose prepared from it inherits that risk. You cannot simply look at the powder and know if its molecular structure has been compromised; only rigorous laboratory testing can confirm its purity, which may not have occurred due to the noted deviations.
Finally, the integrity of the drug's stability is at stake. Sildenafil Citrate is sensitive to environmental factors like heat, light, and humidity. If the manufacturing environment was not controlled according to CGMP standards, the chemical bonds within the powder could begin to degrade before it even leaves the facility in Gujarat, India. This degradation can create unknown byproducts that have never been tested for safety. When a pharmacist compounds a prescription using this unstable ingredient, they are essentially building a final medication on a shaky foundation, exposing patients to variables that were never accounted for in clinical trials.
Who is most at risk
To understand who is actually in the crosshairs of this specific FDA recall, we first need to look closely at what the product is and how it moves through the healthcare system. The item in question is Sildenafil Citrate USP, a generic form of the active ingredient found in well-known medications for erectile dysfunction and pulmonary hypertension. Crucially, the labeling on these 100-gram bags explicitly states "RX ONLY" and "FOR Prescription Compounding Only." This distinction is vital because it means these bulk ingredients are not intended for direct sale to consumers. Instead, they are raw materials sent to compounding pharmacies. Therefore, the individuals at risk are not people who bought a bottle off a shelf, but rather those who have recently visited a specialized pharmacy that prepares custom medication doses for their specific medical needs.
The primary group affected by this recall consists of patients who rely on compounded Sildenafil. These are often individuals whose insurance plans do not cover brand-name drugs, or those who need unique dosages that standard factory-made pills cannot provide. For example, a patient might need a lower dose than is commercially available, or they may be allergic to the inactive fillers in mass-produced tablets. In these cases, a compounding pharmacy purchases bulk ingredients like this batch from suppliers such as Shoolin Pharma Chem LLP and mixes them into creams, capsules, or lozenges tailored to the patient’s prescription. If you have received a compounded medication recently, particularly one prescribed for erectile dysfunction or pulmonary arterial hypertension, you fall into the group that needs to verify their supply against this recall.
When we consider vulnerability, the risks associated with CGMP (Current Good Manufacturing Practice) deviations are less about immediate toxicity for most adults and more about unpredictable therapeutic outcomes. Sildenafil is a potent drug that affects blood pressure and heart function. For elderly patients or those with pre-existing cardiovascular conditions, consistency in dosage is a matter of safety. If the manufacturing process deviated from strict standards, there is a possibility that the concentration of the active ingredient varies between batches or even within the same bag. For a patient whose heart health depends on precise medication levels, this uncertainty can be dangerous. An unexpectedly high dose could lead to a dangerous drop in blood pressure, while an insufficient dose might fail to treat the condition, leading to other health complications.
Furthermore, while the recall is classified as Class II, indicating that use of the product may cause temporary health problems or serious illness but is not likely to cause death, the nature of the hazard remains significant. The risk is highest for those who have already taken medication made from this specific batch (SDC2505001) which expires in April 2030. Because the remedy is not yet stated by the FDA, the uncertainty adds to the anxiety for these patients. They are not just dealing with a potential quality issue; they are dealing with a gap in the safety net that usually protects prescription drug users. It is important to note that if you have never used a compounding pharmacy or do not take Sildenafil, this recall does not impact you directly. Your risk is zero. However, for those dependent on this specific compounded therapy, it is essential to contact their pharmacist immediately to determine if their current supply is affected and to discuss alternative treatment options.
How to tell if you have the recalled item
Identifying whether a specific batch of medication is part of this recall requires careful attention to several distinct details on your packaging. Because this involves a pharmaceutical ingredient rather than a finished consumer product, the labeling conventions are quite specific. You need to verify that every single data point matches the official record exactly; if even one piece of information differs—such as the batch number or the expiration date—it is likely not part of this particular recall event. Please take your time and compare your item against the following criteria.
First, look at the primary label to confirm the brand and product name. The recalled item must be identified as being from Shoolin Pharma Chem LLP. The product itself is labeled as SILDENAFIL CITRATE USP. It is critical to note that this specific batch is marked with the text "RX ONLY 'FOR Prescription Compounding Only'". This designation indicates it is an active pharmaceutical ingredient intended for use by pharmacists or healthcare professionals in compounding prescriptions, not a finished pill ready for direct patient consumption. If your item is a pre-made tablet or capsule from a different manufacturer, it is not included in this notice.
Next, check the physical specifications and quantity. The recall applies specifically to packages containing 0.100 KG of material, which is equivalent to a 100 gm-bag Net Wt. Ensure your package matches this weight exactly. Smaller or larger quantities from the same brand would not be part of this specific Class II recall action.
The most definitive way to verify the item is by checking the unique identification codes. You must find a label that lists the National Drug Code (NDC) as 85702-001-05. Alongside the NDC, look for the specific Batch number: SDC2505001. Finally, verify the Date of Expiry, which must be listed as April 30, 2030. If your batch number differs even slightly (for example, SDC2505002), or if the expiration date is different, that specific unit is not covered by this recall.
Additionally, while you may not see it on every small bag, the manufacturer’s address associated with this product is located in India: Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesana, Gujarat, 382715. The chemical identifier CAS NO. 171599-83-0 may also appear on documentation. Since this product was distributed nationwide across the USA, the location where you purchased it does not help identify it; only the labeling details above will confirm whether your item is part of this recall.
What to do — step by step
If you or your healthcare provider have recently received shipments of Sildenafil Citrate USP from Shoolin Pharma Chem LLP, the most immediate and critical action is to halt any use of this specific material. Because the Food and Drug Administration (FDA) has identified Current Good Manufacturing Practice (CGMP) deviations during their inspection, the integrity of the manufacturing process is in question. While the official recall notice does not explicitly list a remedy such as a return for credit or a repair service, the standard protocol for pharmaceutical ingredients flagged with CGMP violations is to stop using them immediately to prevent any potential contamination or potency issues from entering the compounding process. Do not attempt to use this bulk powder in any prescription preparations, regardless of how small the quantity might be.
The next step involves careful inventory isolation. You should locate the specific batch identified in the recall details: Batch number SDC2505001, with a net weight of 100 grams per bag (0.100 KG) and an NDC of 85702-001-05. If you are a pharmacy or compounding facility, physically separate these bags from your active stock. Place them in a secure, clearly marked area to prevent accidental use by staff who might not be aware of the recall status. This physical segregation is vital because CGMP deviations can sometimes lead to cross-contamination or labeling errors that are not visible to the naked eye. By isolating the product, you protect your patients and your facility from regulatory penalties or health risks associated with using non-compliant materials.
Since the remedy for this specific recall is not stated in the official FDA announcement, you must take proactive steps to resolve the situation. Contact Shoolin Pharma Chem LLP directly to inquire about their instructions for the return or disposal of these goods. They are the manufacturer and distributor listed at Block/Survey no 408, B/H Ratnamani Tubes, Near Maruti Inox, Indrad, Kadi, Mahesana, Gujarat, 382715, India. It is important to document all communications with them, including emails and phone calls, in case you need to prove due diligence to regulatory bodies or your own quality assurance team.
Additionally, notify your regulatory affairs department or legal counsel immediately. A Class II recall indicates that the product could cause temporary health problems or pose a slight risk of serious injury. Even though the hazard is defined as a deviation in manufacturing practices rather than a known adverse event, the potential for undetected quality failures is significant. If you are a distributor, you must ensure that any remaining units in your warehouse are also quarantined and that notifications are sent to any downstream customers who may have received this product before the recall was announced. Do not dispose of the product yourself unless explicitly instructed by the manufacturer or local hazardous waste regulations, as improper disposal could lead to environmental or safety issues.
Your refund, repair, or replacement options
When you encounter a product recall, the most immediate concern is often how to resolve the situation financially and practically. In this specific case involving Shoolin Pharma Chem LLP’s Sildenafil Citrate USP, it is important to approach the remedy with clarity and patience. The official recall documentation provided by the FDA does not explicitly state the specific financial remedy or logistical steps for customers at this time. There is no listed refund policy, repair service, or direct replacement program detailed in the public record. While this might feel uncertain, it is a common occurrence in Class II drug recalls, particularly those involving active pharmaceutical ingredients destined for compounding pharmacies rather than end consumers directly.
Because the product is labeled "FOR Prescription Compounding Only" and is an RX-only substance, the distribution chain is specialized. This means you likely do not hold this item in your personal medicine cabinet, but rather a licensed pharmacy or compounding facility does. Consequently, the standard consumer pathways of calling a retail customer service line to request a refund or mail-in repair are not applicable here. You cannot simply return this item to a store for a cash refund because it is a regulated drug ingredient, not a commercial good sold at retail. The responsibility for handling the recall lies with the entities in the supply chain: the distributor, the compounding pharmacy, and potentially the prescribing physician.
If you believe you may have been prescribed or dispensed medication compounded using this specific batch (Batch SDC2505001), your first step should be to contact the pharmacy that filled your prescription. Do not attempt to dispose of any remaining medication yourself without professional guidance, as improper disposal of pharmaceuticals can pose environmental and safety risks. Instead, ask the pharmacist to verify if their stock includes the recalled NDC 85702-001-05. They are equipped to handle the return process with their supplier or distributor, who will then coordinate with Shoolin Pharma Chem LLP.
For those wondering about compensation, recall remedies in the pharmaceutical industry typically involve the destruction of the non-compliant product rather than a monetary refund to the end user. The "remedy" here is likely the removal of the hazardous or non-compliant ingredient from the market to ensure no further compounding occurs with it. If you have concerns about your health due to potential exposure, please consult your healthcare provider immediately. They can help determine if any action is needed on your part regarding your treatment plan. Always rely on official channels, such as the FDA’s recall database or direct communication from your pharmacy, for updates on this situation, as new information regarding specific restitution or contact details may be added to the record in the future.
What can happen if you ignore it
When a pharmaceutical product is recalled due to Current Good Manufacturing Practice (CGMP) deviations, the primary concern is not necessarily that the medication is "fake," but rather that its quality, purity, or strength cannot be guaranteed. In this specific case involving Shoolin Pharma Chem LLP’s Sildenafil Citrate USP, the FDA identified manufacturing process failures during inspection. Ignoring a Class II recall in this context carries significant risks because Sildenafil is a potent drug typically used to treat erectile dysfunction and pulmonary arterial hypertension. Even minor variations in how the active ingredient is processed can lead to serious health complications that are difficult to anticipate without laboratory testing.
The most immediate danger of continuing to use a drug manufactured under CGMP deviations is the risk of incorrect dosing. The "USP" designation indicates that the substance should meet strict United States Pharmacopeia standards for identity, strength, quality, and purity. When manufacturing controls fail, the actual amount of Sildenafil Citrate in each batch may vary from what is labeled. If the concentration is lower than stated, you may experience treatment failure, which can be particularly distressing for individuals relying on this medication for specific medical conditions. Conversely, if the concentration is higher than expected, you face an increased risk of overdose symptoms. These can include dangerously low blood pressure, prolonged and painful erections (priapism), vision changes, hearing loss, or severe headaches. Because Sildenafil affects blood vessels throughout the body, an unpredictable dose can strain the cardiovascular system in ways that are both sudden and severe.
Beyond dosage inconsistency, CGMP deviations often raise concerns about contamination or impurities. The manufacturing environment must be strictly controlled to prevent microbial growth, cross-contamination with other substances, or the presence of residual solvents from the chemical synthesis process. If these controls were compromised during the production of this specific batch (SDC2505001), you could be exposed to harmful contaminants that are not apparent to the naked eye. These impurities can cause allergic reactions, toxic responses, or other adverse effects that have nothing to do with the intended pharmacological action of the drug. Unlike a simple expiration date issue, where potency simply fades, manufacturing defects can introduce unpredictable chemical variables into your body.
There is also a critical safety gap regarding medical supervision. Sildenafil interacts dangerously with nitrates (often prescribed for chest pain) and certain other medications. A qualified healthcare provider selects the dose based on your health profile to mitigate these risks. When you use an unverified, recalled product obtained outside of standard pharmacy channels or without current professional oversight, you lose that safety net. You are essentially self-medicating with a substance whose consistency is in question, making it impossible for any doctor to accurately manage your care if complications arise. While no specific injuries have been reported by the FDA for this particular recall yet, the potential for harm remains real because the fundamental guarantee of pharmaceutical quality has been broken.
Finally, ignoring the recall delays your access to safe alternatives. By continuing to use a potentially compromised product, you are not only risking your health but also wasting time that could be spent obtaining a verified, high-quality replacement from a trusted source. In the world of prescription compounding and active pharmaceutical ingredients, trust is built on rigorous documentation and inspection. When that trust is violated by regulatory findings, the safest path is always to step back and let the experts ensure your medication meets the necessary standards for human consumption.
Staying safe: broader tips
When it comes to pharmaceuticals and medical compounds, safety is less about a single event and more about building a reliable system of checks and balances in your daily life. While we cannot control the manufacturing processes that occur thousands of miles away, we can take meaningful steps to ensure that the medications we rely on are handled with the highest degree of care. The most powerful tool you have as a consumer is vigilance regarding where and how you source your prescription ingredients. Always verify that your pharmacy or compounding provider is accredited by recognized bodies such as the Pharmacy Compounding Accreditation Board (PCAB) or is licensed in strict accordance with state laws. Reputable providers will always be transparent about their sourcing practices and willing to provide documentation proving that their active pharmaceutical ingredients meet United States Pharmacopeia (USP) standards.
Beyond sourcing, maintaining a personal record of your medications is an often-overlooked but critical safety habit. Keep a simple log or use a secure digital app to track the names of your medications, the pharmacies where you fill them, and any lot numbers or expiration dates associated with them. This practice not only helps you manage your health but also makes it significantly easier to act quickly if a recall is announced. If a notification does come out, having your records on hand allows you to identify exactly which products you may possess without needing to dig through old receipts or packaging, reducing stress and potential confusion during a time when clarity is essential.
It is also wise to stay informed about the broader landscape of drug safety. The FDA issues numerous recalls and safety alerts each month for various reasons, ranging from minor labeling errors to serious contamination issues. Subscribing to official FDA email alerts or regularly visiting their official website can help you stay ahead of potential risks before they affect your health. Do not rely solely on social media feeds or third-party news aggregators for this information; official government channels provide the most accurate and timely data. Additionally, always read the medication guide provided with new prescriptions. These guides contain crucial information about proper storage conditions, potential interactions, and signs of adverse reactions that you should watch for.
- Verify Your Provider: Ensure your compounding pharmacy is licensed and follows strict quality control protocols.
- Maintain Records: Keep a digital or physical log of your medications, including lot numbers and expiration dates.
- Stay Informed: Sign up for FDA safety alerts to receive timely updates on recalls and health advisories.
- Read Guides: Always review the medication guide that comes with new prescriptions for storage and usage instructions.
Finally, remember that safety is a shared responsibility. If you have questions about the source of your medications or notice any unusual changes in appearance, smell, or effect, contact your healthcare provider or pharmacist immediately. They are your best resource for navigating these complexities and ensuring that your treatment plan remains safe and effective. By staying proactive and informed, you help protect not only yourself but also your community from potential health risks.